Windtree Therapeutics Announces Reverse Stock Split
April 18, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
April 17, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
April 08, 2024 16:48 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an...
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
February 01, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
January 31, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
January 25, 2024 08:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
January 17, 2024 08:00 ET
|
Windtree Therapeutics
Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for...
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
January 02, 2024 16:05 ET
|
Windtree Therapeutics
The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute...
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
December 18, 2023 08:00 ET
|
Windtree Therapeutics
SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime...
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
November 16, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...